ClinicalTrials.gg
CompletedNCT01311505Updated Jul 30, 2012Results posted

Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)

A Phase 1 interventional study of Myrin© 2 (Rifampicin + Isoniazid) and Rimactane® (Rifampicin) in Tuberculosis, sponsored by Pfizer. Completed at 1 site in Philippines. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-07-30.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing rifampin in Tuberculosis — 6 open to participants now, 7 under way, 3 of them phase 3. Rifampin · Tuberculosis.

Enrollment
26th of 34
21 · median 129
Started
2011
with 2 others
Phase 1
10 of 34
none open now
Registered
11th of 34
by date

Among the 34 studies testing rifampin in Tuberculosis, this one is the 26th largest by enrollment, is one of 3 that started in 2011, is one of 10 in phase 1, and was the 11th registered.

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

6 of the 34 studies testing rifampin in Tuberculosis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About rifampin

Rifampin: first FDA approval 1971 (RIFADIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing rifampin in Tuberculosis, or all of them as a file.
02

Study summary

This study is done to demonstrate bioequivalence of rifampicin component in Myrin© 2 Fixed-Dose Combination Tablet (each contains 75 mg isoniazid and 150 mg rifampicin, Pfizer Inc) with equivalent dose of the reference Rimactane® capsule (each contains 300 mg rifampicin, Novartis Sandoz) in healthy Filipino male subjects. This study also aims to determine the safety and tolerability of Myrin© 2 tablets and Rimactane® capsules in these subjects.

03

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • bioequivalence; rifampicin
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects between the ages of 18 and 55 years, inclusive.
  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
  • An document signed and dated by the subject.
  • Subjects willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • Any condition possibly affecting drug absorption (e.g., gastrectomy).
  • A positive urine drug screen.
  • History of regular alcohol consumption exceeding 21 drinks/week (1 drink = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of hard liquor) within 6 months of screening.
  • Treatment with an drug within 3 months (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
  • 12-lead demonstrating >450 msec at screening. If QTc exceeds 450 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility.
  • History of previous treatment for TB or is suspected of suffering from TB.
  • Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal medication, herbal supplements and hormone replacement therapy must be discontinued 28 days prior to the first dose of study medication. As an exception, acetaminophen / paracetamol may be used at doses of less than 1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
  • Blood donation of approximately 1 pint (500 ml) within 56 days prior to dosing.
  • A history of to any of the study medications or related substances, or to any of the ingredients used in the study drug formulations.
  • Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  • Recent history of diarrhea (2 weeks).
  • Recent use of oral (2 weeks) or IV (2-3 months) antibiotics to assure normal bowel flora at study start.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Active comparator
    A

    Test

    Drug: Myrin© 2 (Rifampicin + Isoniazid)

  • Active comparator
    B

    Reference

    Drug: Rimactane® (Rifampicin)

Interventions

  • DrugMyrin© 2 (Rifampicin + Isoniazid)

    Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg

    Also known as: Myrin© 2 (Pfizer Inc.)

  • One (1) capsule of Rifampicin 300 mg

    Also known as: Rimactane® (Novartis Sandoz)

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t])

    AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hours (hrs) post-dose

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose

Secondary outcomes

  1. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose

  2. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])

    AUC (0-∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose

  3. Plasma Decay Half-life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose

  4. Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)

    AUC%extrapolated is the extrapolated area under the plasma concentration time profile following the last measured concentration. It is calculated as (AUC \[0-∞\] minus AUC\[0-10\])\*100/ AUC (0-∞), where AUC (0-∞) = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUC(0-10) = area under the plasma concentration time-curve from zero (pre-dose) to the last quantifiable concentration.

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose

Other outcomes

  1. Number of Participants With Abnormal Safety Laboratory Test Values

    Participants were evaluated for following safety laboratory tests: Hematology, chemistry, urinalysis.

    Time frame: Screening and Follow-up (1 week post-baseline)

  2. Clinically Significant Change From Baseline Supine Blood Pressure (BP)

    Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.

    Time frame: Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)

  3. Clinically Significant Change From Baseline Pulse Rate

    Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.

    Time frame: Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)

  4. Clinically Significant Change From Baseline Oral Temperature

    Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.

    Time frame: Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)

  5. Clinically Significant Change From Baseline Respiratory Rate

    Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.

    Time frame: Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)

  6. Number of Participants With Adverse Events (AEs)

    Any untoward medical occurrence in a participant who received study treatment was considered an AE without regard to possibility of causal relationship.

    Time frame: Baseline (Day 0), Day 1 and Follow-up (1 week post-baseline)

07

Results

Posted Jul 30, 2012

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestoneMyrin 2 First, Then RimactaneRimactane First, Then Myrin 2
Started1011
Completed1010
Not completed01
Withdrew: Protocol violation01
Washout Period (at Least 7 Days)
Participant flow — Washout Period (at Least 7 Days)
MilestoneMyrin 2 First, Then RimactaneRimactane First, Then Myrin 2
Started1010
Completed1010
Not completed00
Second Intervention Period
Participant flow — Second Intervention Period
MilestoneMyrin 2 First, Then RimactaneRimactane First, Then Myrin 2
Started1010
Completed1010
Not completed00

Outcome measures

PrimaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t])

AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hours (hrs) post-dose
Reported as:
Geometric mean · microgram*hour/milliliter (mcg*h/mL)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t])
microgram*hour/milliliter (mcg*h/mL)Myrin 2Rimactane
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t])38.59 ± 24.9938.81 ± 21.95
Statistical analysis
  • Myrin 2 vs Rimactane · Ratio of adjusted geometric means: 98.90 · 90% CI 92.98 to 105.20
PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose
Reported as:
Geometric mean · mcg/mL
Maximum Observed Plasma Concentration (Cmax)
mcg/mLMyrin 2Rimactane
Maximum Observed Plasma Concentration (Cmax)7.89 ± 24.898.02 ± 22.35
Statistical analysis
  • Myrin 2 vs Rimactane · Ratio of adjusted geometric means: 98.24 · 90% CI 87.77 to 109.97
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose
Reported as:
Median · hrs
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrsMyrin 2Rimactane
Time to Reach Maximum Observed Plasma Concentration (Tmax)2.0 (1.0 to 3.0)1.0 (1.0 to 3.0)
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])

AUC (0-∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose
Reported as:
Geometric mean · mcg*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])
mcg*hr/mLMyrin 2Rimactane
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])47.72 ± 30.5447.15 ± 25.32
Statistical analysis
  • Myrin 2 vs Rimactane · Ratio of adjusted geometric means: 100.25 · 90% CI 94.44 to 106.41
SecondaryPlasma Decay Half-life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose
Reported as:
Mean · hrs
Plasma Decay Half-life (t1/2)
hrsMyrin 2Rimactane
Plasma Decay Half-life (t1/2)4.0750 ± 1.07773.8635 ± 0.8347
SecondaryExtrapolated Area Under the Curve (AUC Percent [%] Extrapolated)

AUC%extrapolated is the extrapolated area under the plasma concentration time profile following the last measured concentration. It is calculated as (AUC \[0-∞\] minus AUC\[0-10\])\*100/ AUC (0-∞), where AUC (0-∞) = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUC(0-10) = area under the plasma concentration time-curve from zero (pre-dose) to the last quantifiable concentration.

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose
Reported as:
Geometric mean · Percent AUC
Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)
Percent AUCMyrin 2Rimactane
Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)18.84 ± 38.4717.53 ± 30.23
Other pre-specifiedNumber of Participants With Abnormal Safety Laboratory Test Values

Participants were evaluated for following safety laboratory tests: Hematology, chemistry, urinalysis.

Time frame:
Screening and Follow-up (1 week post-baseline)
Reported as:
Number · participants
Number of Participants With Abnormal Safety Laboratory Test Values
participantsMyrin 2Rimactane
Screening00
Follow-up00
Other pre-specifiedClinically Significant Change From Baseline Supine Blood Pressure (BP)

Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.

Time frame:
Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)
Reported as:
Mean · millimeters of mercury (mmHg)

No measurements were reported for this outcome.

Other pre-specifiedClinically Significant Change From Baseline Pulse Rate

Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.

Time frame:
Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)
Reported as:
Mean · beats per minute

No measurements were reported for this outcome.

Other pre-specifiedClinically Significant Change From Baseline Oral Temperature

Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.

Time frame:
Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)
Reported as:
Mean · Degrees Celsius

No measurements were reported for this outcome.

Other pre-specifiedClinically Significant Change From Baseline Respiratory Rate

Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.

Time frame:
Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)
Reported as:
Mean · respirations/minute

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Adverse Events (AEs)

Any untoward medical occurrence in a participant who received study treatment was considered an AE without regard to possibility of causal relationship.

Time frame:
Baseline (Day 0), Day 1 and Follow-up (1 week post-baseline)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsMyrin 2Rimactane
Day 000
Day 100
Follow-up00

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Myrin 2—0/20 (0%)0/20 (0%)
Rimactane—0/21 (0%)0/21 (0%)

Baseline characteristics

Age, Customized
Age, Customized(participants)Participants Eligible for Analysis
18 to 22 years12
23 to 27 years4
28 to 32 years2
33 to 37 years2
Sex: Female, Male
Sex: Female, Male(Participants)Participants Eligible for Analysis
Female0
Male20
08

Study locations

1 site
  • Pfizer Investigational Site
    Dasmariñas City, 4114, Philippines
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2011
First posted
Mar 9, 2011
Start
Apr 2011
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
Jul 30, 2012
Last update
Jul 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01311505
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 9, 2011
Start date
Apr 2011
Primary completion
May 2011
Completion
May 2011
Results posted
Jul 30, 2012
Last update
Jul 30, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifampin

Start the discussion